Zobrazeno 1 - 10 of 26 pro vyhledávání: '"Labenski MT"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Novel Corrector for Variants of SLC6A8: A Therapeutic Opportunity for Creatine Transporter Deficiency.
Autor: Gechijian LN; Jnana Therapeutics, Boston, Massachusetts 02210, United States., Muncipinto G; Third Harmonic Bio, Cambridge, Massachusetts 02139, United States., Rettenmaier TJ; Jnana Therapeutics, Boston, Massachusetts 02210, United States., Labenski MT; Jnana Therapeutics, Boston, Massachusetts 02210, United States., Rusu V; Apple Tree Partners, New York, New York 10169, United States., Rosskamp L; Jnana Therapeutics, Boston, Massachusetts 02210, United States., Conway L; Jnana Therapeutics, Boston, Massachusetts 02210, United States., van Kalken D; Jnana Therapeutics, Boston, Massachusetts 02210, United States., Gross L; Oregon State University, Portland, Oregon 97331, United States., Iantosca G; Atavistik Bio, Cambridge, Massachusetts 02140, United States., Crotty W; Neumora Tx, Watertown, Massachusetts 02472, United States., Mathis R; Jnana Therapeutics, Boston, Massachusetts 02210, United States., Park H; Jnana Therapeutics, Boston, Massachusetts 02210, United States., Rabin B; Brigham and Women's Hospital, Boston, Massachusetts 02115, United States., Westgate C; DG Medicines, Boston, Massachusetts 02115, United States., Lyons M; University of California, San Francisco, California 90095, United States., Deshusses C; University of North Carolina, Chapel Hill, North Carolina 27599, United States., Brandon N; Neumora Tx, Watertown, Massachusetts 02472, United States., Brown DG; Jnana Therapeutics, Boston, Massachusetts 02210, United States., Blanchette HS; Jnana Therapeutics, Boston, Massachusetts 02210, United States., Pullen N; ArtBio, Cambridge, Massachusetts 02139, United States., Jones LH; Center for Protein Degradation, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, United States., Barrish JC; RA Capital Ventures, Boston, Massachusetts 02116, United States.
Publikováno v: ACS chemical biology [ACS Chem Biol] 2024 Nov 15; Vol. 19 (11), pp. 2372-2382. Date of Electronic Publication: 2024 Oct 17.
Zobrazit plný text záznamu
5
Akademický článek
SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine.
Autor: Wobst HJ; Jnana Therapeutics, Boston, Massachusetts, USA., Viader A; Jnana Therapeutics, Boston, Massachusetts, USA., Muncipinto G; Jnana Therapeutics, Boston, Massachusetts, USA., Hollibaugh R; Jnana Therapeutics, Boston, Massachusetts, USA., van Kalken D; Jnana Therapeutics, Boston, Massachusetts, USA., Burkhart CT; Jnana Therapeutics, Boston, Massachusetts, USA., Cantin SM; Jnana Therapeutics, Boston, Massachusetts, USA., Bates RM; Jnana Therapeutics, Boston, Massachusetts, USA., Regimbald-Dumas Y; Jnana Therapeutics, Boston, Massachusetts, USA., Gross L; Jnana Therapeutics, Boston, Massachusetts, USA., Antalek MT; Jnana Therapeutics, Boston, Massachusetts, USA., Zweig JE; Jnana Therapeutics, Boston, Massachusetts, USA., Wu F; Jnana Therapeutics, Boston, Massachusetts, USA., Rettenmaier TJ; Jnana Therapeutics, Boston, Massachusetts, USA., Labenski MT; Jnana Therapeutics, Boston, Massachusetts, USA., Pullen N; Jnana Therapeutics, Boston, Massachusetts, USA., Blanchette HS; Jnana Therapeutics, Boston, Massachusetts, USA., Henderson JL; Jnana Therapeutics, Boston, Massachusetts, USA., Weng HH; HW MedAdvice LLC, San Diego, California, USA., Vaughn TA; Jnana Therapeutics, Boston, Massachusetts, USA., Brown DG; Jnana Therapeutics, Boston, Massachusetts, USA., Throup JP; Jnana Therapeutics, Boston, Massachusetts, USA., Barrish JC; Jnana Therapeutics, Boston, Massachusetts, USA.
Publikováno v: JCI insight [JCI Insight] 2024 Nov 08; Vol. 9 (21). Date of Electronic Publication: 2024 Nov 08.
Zobrazit plný text záznamu
6
Akademický článek
A Probe-Free Occupancy Assay to Assess a Targeted Covalent Inhibitor of Receptor Tyrosine-Protein Kinase erbB-2.
Autor: Xue L; Leads Discovery & Optimization, Bristol Myers Squibb, 250 Water Street, Cambridge, Massachusetts 02141, United States., van Kalken D; Leads Discovery & Optimization, Bristol Myers Squibb, 250 Water Street, Cambridge, Massachusetts 02141, United States., James EM; Leads Discovery & Optimization, Bristol Myers Squibb, 250 Water Street, Cambridge, Massachusetts 02141, United States., Giammo G; Leads Discovery & Optimization, Bristol Myers Squibb, 250 Water Street, Cambridge, Massachusetts 02141, United States., Labenski MT; Leads Discovery & Optimization, Bristol Myers Squibb, 250 Water Street, Cambridge, Massachusetts 02141, United States., Cantin S; Leads Discovery & Optimization, Bristol Myers Squibb, 250 Water Street, Cambridge, Massachusetts 02141, United States., Fahnoe K; Leads Discovery & Optimization, Bristol Myers Squibb, 250 Water Street, Cambridge, Massachusetts 02141, United States., Worm K; Leads Discovery & Optimization, Bristol Myers Squibb, 250 Water Street, Cambridge, Massachusetts 02141, United States., Wang Z; Leads Discovery & Optimization, Bristol Myers Squibb, 250 Water Street, Cambridge, Massachusetts 02141, United States., Corin AF; Leads Discovery & Optimization, Bristol Myers Squibb, 250 Water Street, Cambridge, Massachusetts 02141, United States.
Publikováno v: ACS pharmacology & translational science [ACS Pharmacol Transl Sci] 2024 Aug 01; Vol. 7 (8), pp. 2507-2515. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024).
Zobrazit plný text záznamu
7
Akademický článek
SMaSh: A Streptavidin Mass Shift Assay for Rapidly Quantifying Target Occupancy by Irreversible Inhibitors.
Autor: Labenski MT; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, New Jersey 08648, United States., Bateman LA; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, New Jersey 08648, United States., Voortman LT; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, New Jersey 08648, United States., Giammo G; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, New Jersey 08648, United States., Cantin S; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, New Jersey 08648, United States., Qiao L; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, New Jersey 08648, United States., Corin AF; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, New Jersey 08648, United States.
Publikováno v: Biochemistry [Biochemistry] 2021 Oct 05; Vol. 60 (39), pp. 2915-2924. Date of Electronic Publication: 2021 Sep 23.
Zobrazit plný text záznamu
8
Akademický článek
Labeling Preferences of Diazirines with Protein Biomolecules.
Autor: West AV; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States., Muncipinto G; Jnana Therapeutics, Boston, Massachusetts 02210, United States., Wu HY; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States., Huang AC; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States., Labenski MT; Jnana Therapeutics, Boston, Massachusetts 02210, United States., Jones LH; Dana-Farber Cancer Institute, 360 Longwood Avenue, Boston, Massachusetts 02215, United States., Woo CM; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States.
Publikováno v: Journal of the American Chemical Society [J Am Chem Soc] 2021 May 05; Vol. 143 (17), pp. 6691-6700. Date of Electronic Publication: 2021 Apr 20.
Zobrazit plný text záznamu
9
Akademický článek
S-adenosyl-l-methionine protection of acetaminophen mediated oxidative stress and identification of hepatic 4-hydroxynonenal protein adducts by mass spectrometry.
Autor: Brown JM; Department of Pharmacology, Physiology and Toxicology, Joan C. Edwards School of Medicine, Huntington, WV, USA., Kuhlman C; Southwest Environmental Health Sciences Center, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona Health Sciences Center, Tucson, AZ, USA., Terneus MV; Department of Pharmacology, Physiology and Toxicology, Joan C. Edwards School of Medicine, Huntington, WV, USA., Labenski MT; Southwest Environmental Health Sciences Center, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona Health Sciences Center, Tucson, AZ, USA., Lamyaithong AB; Department of Pharmacology, Physiology and Toxicology, Joan C. Edwards School of Medicine, Huntington, WV, USA., Ball JG; Department of Pharmacology, Physiology and Toxicology, Joan C. Edwards School of Medicine, Huntington, WV, USA., Lau SS; Southwest Environmental Health Sciences Center, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona Health Sciences Center, Tucson, AZ, USA., Valentovic MA; Department of Pharmacology, Physiology and Toxicology, Joan C. Edwards School of Medicine, Huntington, WV, USA. Electronic address: Valentov@marshall.edu.
Publikováno v: Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2014 Dec 01; Vol. 281 (2), pp. 174-84. Date of Electronic Publication: 2014 Sep 22.
Zobrazit plný text záznamu
10
Akademický článek
In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.
Autor: Tjin Tham Sjin R; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California rtjin@celgene.com., Lee K; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Walter AO; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Dubrovskiy A; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Sheets M; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Martin TS; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Labenski MT; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Zhu Z; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Tester R; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Karp R; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Medikonda A; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Chaturvedi P; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Ren Y; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Haringsma H; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Etter J; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Raponi M; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Simmons AD; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Harding TC; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Niu D; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Nacht M; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Westlin WF; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Petter RC; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Allen A; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California., Singh J; Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2014 Jun; Vol. 13 (6), pp. 1468-79. Date of Electronic Publication: 2014 Apr 10.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje